There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TrkA


TrkA Molecule Information

Name:Nerve growth factor receptor Trk-A
Target Synonym:Neurotrophic tyrosine kinase receptor type 1?Trk-A?NTRK1?MTC ?High affinity nerve growth factor receptor?TRK1-transforming tyrosine kinase protein?Tropomyosin-related kinase A?TRKA?Tyrosine kinase receptor A?TRK?Tyrosine kinase receptor?gp140trk?p140-TrkA
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:22
Lastest Research Phase:Approved

TrkA Molecule Synonym Name


TrkA Molecule Background

TrkA References

TrkA Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Regorafenib Monohydrate BAY-73-4506; DAST,BAY73-4506,BAY 73-4506 Approved Bayer, Onyx Pharmaceutical STIVARGA fda BAYER HEALTHCARE PHARMS 2013-02-25 Gastrointestinal stromal tumors (GISTs), Metastatic colorectal cancer (CRC), Hepatocellular carcinoma (HCC) Details
Larotrectinib sulfate LOXO-101 sulfate; ARRY-470 (free base); LOXO-101 (free base); RDF76R62ID Approved Array BioPharma, Loxo Oncology, Bayer VITRAKVI fda Solid tumours LOXO ONCOLOGY INC 2018-11-26 Solid tumours Details

TrkA Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ropotrectinib TPX-0005,TPX0005,TPX 0005 Phase Ⅱ Non small cell lung cancer (NSCLC), Solid tumours Details
Belizatinib TSR-011,TSR011 Phase Ⅱ Amgen, Tesaro Non small cell lung cancer (NSCLC), Solid tumours, Lymphoma Details
AZD-7451 AZD-7451,AZD7451 Phase Ⅰ AstraZeneca, National Cancer Institute Glioblastoma multiforme Details
VMD-928 VMD-928 Phase Ⅰ VM Oncology Solid tumours, Lymphoma Details
AZD-6918 AZD-6918 Phase Ⅰ AstraZeneca Solid tumours Details
Nerve growth factor (Genentech) Phase Ⅲ Chiron, Amgen, Genentech, Ceregene Neuropathic pain, Diabetic neuropathy, Alzheimer's disease (AD), Herpes simplex virus (HSV) infection, Peripheral  neuropathy Details
FX-007 FX-007,FX007;FX 007 Preclinical AstraZeneca, Flexion Therapeutics Postoperative pain, Musculoskeletal pain Details
BN-201 BN-201 Phase Ⅰ Bionure Optic neuritis, Neuromyelitis optica (NMO) Details
GZ-389988 GZ-389988; GZ-389988A; GR-389988 Phase Ⅱ Sanofi Osteoarthritis (OA) Details
Altiratinib DCC-22701; DCC-2701; DP-5164; T678746713,DP5164,DCC2701, Phase Ⅰ Deciphera Solid tumours Details
Entrectinib NMS-E628; RXDX-101 NDA Filing Nerviano Medical Sciences, Ignyta Pharma, Roche, Chugai Neuroblastoma, Non small cell lung cancer (NSCLC), Solid tumours, Colorectal cancer, Acute myeloid Leukemia (AML) Details
CE-245677 CE-245677 Phase Ⅰ Pfizer Cancer Details
DS-6051 DS-6051; DS-6051a; DS-6051b,DS6051,DS6051a,DS6051b Phase Ⅰ Daiichi Sankyo, AnHeart Therapeutics Solid tumours Details
GBR-900 GBR-900; hMNAC-13; MNAC-13; BXL-1H5 Phase Ⅰ Lay Line Genomics, Glenmark Pharma Chronic pain Details
VM-902A VM-902A; VM-902,VM902A,VM902A Phase Ⅱ VM Discovery, Purdue Pharma Pain Details
Milciclib PHA-848125C; PHA-125; PHA-848125; PHA-848125AC; TZLS-201 Phase Ⅱ Nerviano Medical Sciences, Tiziana Life Sciences Thymic tumor Details
AK-1830 (Array BioPharma) AK-1830 Phase Ⅰ Array BioPharma Inflammation Details
PLX-7486 PLX-7486; PLX7486-TsOH Phase Ⅲ Daiichi Sankyo Pancreatic cancer Details
DBPR-114 Phase Ⅰ National Health Research Institutes Cancer Details
Pegcantratinib CT 301/P; CT 327; K-252a-PEG2K; Pegylated K252A; SNA-120 Phase Ⅱ Cephalon, Creabilis Plaque psoriasis, Atopic dermatitis Details
ASP-7962 ASP-7962,ASP7962 Phase Ⅱ Astellas Pain Details
SNA-125 CT-340; SNA-125 Phase Ⅱ Creabilis, Sienna Biopharmaceuticals Pruritus, Psoriasis, Atopic dermatitis Details

This web search service is supported by Google Inc.